The NHS has provided health and care, free at the point of delivery, for more than 75 years. It is rightly held as a national ...

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA1064 22 May 2025 22 May ...

The appraisal committee sub-group has prepared final draft guidance (FDG) on linzagolix for treating symptoms of endometriosis and submitted it to NICE. The FDG has been sent to consultees for this ...

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

This guidance has been updated and replaced by NICE guideline NG217. Back to top ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because ...

The meeting will take place as a webinar via Zoom, a secure web conferencing tool. This meeting will run from 10:00am to 4:00pm, although timings may be subject to change. You will receive your ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...